Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban

References

• Brunenberg DE, van Steyn MJ, Sluimer JC, Bekebrede LL, Bulstra SK, Joore MA. Joint recovery program versus usual care: an economic evaluation of a clinical pathway for joint replacement surgery. Med. Care43, 1018–1026 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopedic surgery: clinical potential of direct thrombin inhibitors. Drugs64(6), 577–595 (2004).
   PubMed Web of Science ®Google Scholar
• Ostendorf M, Johnell O, Malchau H, Dhert WJA, Schrijvers AJP, Verbout AJ. The epidemiology of total hip replacement in The Netherlands and Sweden: present status and future needs. Acta Orthop. Scand.73(3), 282–286 (2002).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3), 338–400 (2004).
   PubMedGoogle Scholar
• Samama CM, Albaladejo P, Benhamou D et al. Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur. J. Anaesthesiol.23(2), 95–116 (2006).
   PubMedGoogle Scholar
• Buller HR, van der Meer J, Oudkerk M. CBO guideline. Deep venous thrombosis and pulmonary embolism; revision of the earlier guidelines. Dutch Organization for Quality Assurance in Hospitals. Ned. Tijdschr. Geneeskd.144(32), 1531–1537 (2000).
   PubMedGoogle Scholar
• Ettema HB, Hoppener MR, Henny CP, Buller HR, Verheyen CCPM. Compliance of Dutch orthopedic departments with national guidelines on thromboprophylaxis. A survey of Dutch orthopedic thromboprophylaxis. Acta Orthop.76(1), 99–103 (2005).
   PubMed Web of Science ®Google Scholar
• Schonenberg D, van Meeteren M, Nelissen RGHH, van der Horst-Bruinsma IE, Pöll RG, Nurmohamed MT. Thrombosis prevention in orthopedic surgery: clinical practice in the Netherlands in 2002. Ned. Tijdschr. Geneeskd.147(38), 1856–1860 (2003).
   PubMedGoogle Scholar
• Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet359(9319), 1715–1720 (2002).
   PubMed Web of Science ®Google Scholar
• Swierstra BA, Stibbe J, Schouten HJA. Prevention of thrombosis after hip arthroplasty. A prospective study of preoperative oral anticoagulants. Acta Orthop. Scand.59(2), 139–143 (1988).
   PubMed Web of Science ®Google Scholar
• Samama CM, Vray M, Barre J et al. SACRE Study Investigators. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch. Intern. Med.162(19), 2191–2196 (2002).
   PubMed Web of Science ®Google Scholar
• Hamulyak K, Lensing AWA, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb. Haemost.74(6), 1428–1431 (1994).
   Google Scholar
• Eriksson BI, Dahl OE, Buller HR et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost.3(1), 103–111 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris L, Dahl OE et al. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement J. Thromb. Haemost.4(1), 121–128 (2006).
   PubMed Web of Science ®Google Scholar
• Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J. Thromb. Haemost.2(7), 1058–1070 (2004).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med.162(16), 1833–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N. Engl. J. Med.353(10), 1028–1040 (2005).
   PubMed Web of Science ®Google Scholar
• Colwell C, Mouret P. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Semin. Vasc. Med.5(3), 266–275 (2005).
   PubMedGoogle Scholar
• Annemans L, Minjoulat-Rey MC, De Knock M et al. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery in Belgium. Acta Clin. Belg.59(6), 346–357 (2004).
   PubMed Web of Science ®Google Scholar
• Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am. J. Cardiovasc. Drugs5(2), 121–130 (2005).
   PubMedGoogle Scholar
• Gordois A, Posnett J, Borris L et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J. Thromb. Haemost.1(10), 2167–2174 (2003).
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur. J. Health Econ.4(4), 254–262 (2003).
   PubMedGoogle Scholar
• Wade WE, Spruill WJ, Leslie RB. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am. J. Orthop.32(4), 201–205 (2003).
   PubMedGoogle Scholar
• Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch. Intern. Med.162(13), 1451–1456 (2002).
   PubMedGoogle Scholar
• Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial. Lancet359(93), 1721–1726 (2002).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Sonaglia F. Prevention of venous thromboembolism in high risk patients. Haematologica82(4), 496–502 (1997).
   PubMed Web of Science ®Google Scholar
• Dobesh PP. Evidence for extended prophylaxis in the setting of orthopedic surgery. Pharmacotherapy24(7), 73–81 (2004).
   Google Scholar
• Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA283(21), 2816–2821 (2000).
   PubMed Web of Science ®Google Scholar
• Ellis MH, Elis A. Perioperative venous thromboembolism prophylaxis in Israel: a survey of academic surgical departments. Eur. J. Haematol.73(2), 104–108 (2004).
   PubMedGoogle Scholar
• Verhaeghe R. Extended prophylaxis of venous thromboembolism in major orthopedic surgery. Acta Orthop. Belg.71(3), 255–259 (2005).
   PubMedGoogle Scholar
• Stratton MA, Anderson FA, Bussey HI et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch. Intern. Med.160(3), 334–340 (2000).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Davidson BL, Haas SK. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J. Thromb. Haemost.2(2), 221–227 (2004).
   PubMedGoogle Scholar
• Samama MM, Dahl OE, Mismetti P et al. An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica91(1), 64–70 (2006).
   PubMed Web of Science ®Google Scholar
• van Geest-Daalderop JHH, Sturk A, Levi M, Adriaansen HJ. Extent and quality of anti-coagulation treatment with coumarin derivatives by the Dutch Thrombosis Services. Ned. Tijdschr. Geneeskd.148(15), 730–735 (2004).
   PubMedGoogle Scholar
• Schalekamp T, van Geest-Daalderop JHH, de Vries-Goldschmeding H, Conemans J, Bernsen MJ, de Boer A. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin. Pharmacol. Ther.75(5), 394–402 (2004).
   PubMed Web of Science ®Google Scholar